# Matinas Biopharma (MTNB) — News

MTNB · AMEX · Stock

Canonical page: https://www.lighthorse.io/tickers/mtnb/news

## Recent headlines

- [Matinas Biopharma - Reverse stock split effective September 28, 2026 - SEC filing](https://www.ainvest.com/news/matinas-biopharma-reverse-stock-split-effective-september-28-2026-sec-filing-2609) — AInvest Wire, Sep 16, 2026
  Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has announced that a one-for-fifty (1:50) reverse stock split became effective on September 28, 2026, following the completion of necessary regulatory and corporate procedures. The reverse stock split was previously approved by the company’s…
- [Matinas Biopharma - Board approves reverse stock split at one-for-fifteen ratio - SEC filing](https://www.ainvest.com/news/matinas-biopharma-board-approves-reverse-stock-split-fifteen-ratio-sec-filing-2609) — AInvest Wire, Sep 16, 2026
  Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) has announced that its Board of Directors has approved a reverse stock split at a one-for-fifteen ratio, following a Special Meeting of Stockholders. The proposal was submitted for stockholder approval in a preliminary proxy statement filed with…
- [Matinas Biopharma - Initial term of agreement expires two years after commercial operations commence](https://www.ainvest.com/news/matinas-biopharma-initial-term-agreement-expires-years-commercial-operations-commence-2609) — AInvest Wire, Sep 14, 2026
- [Matinas Biopharma receives notice of non-compliance with NYSE American continued listing standards](https://www.ainvest.com/news/matinas-biopharma-receives-notice-compliance-nyse-american-continued-listing-standards-2609) — AInvest Wire, Sep 4, 2026
  Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has received a notice of non-compliance with the continued listing standards of the NYSE American. The notice, issued on June 24, 2026, cited the company’s failure to meet the stockholders’ equity requirements outlined in Sections 1003(a)(ii)…
- [Matinas Biopharma - incurs no termination penalties or expenses from sales agreement termination - SEC filing](https://www.ainvest.com/news/matinas-biopharma-incurs-termination-penalties-expenses-sales-agreement-termination-sec-filing-2607) — AInvest Wire, Jul 24, 2026
  Matinas Biopharma Inc. has disclosed in a recent SEC filing that it incurred no termination penalties or expenses following the termination of a sales agreement [1]. The company previously entered into the agreement to facilitate the distribution of one of its pharmaceutical products. According to…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).